Hans

@dmschoi

Web3, DeSci, Healthcare, Blockchain

Joined January 2022

151 Following

16 Followers

149 Posts

dmschoi retweeted

Mars_DeFi

@Mars_DeFi

19 days ago

DeSci’s market cap has reached $384M as AI agents compress peptide drug discovery into 24-hour research pipelines. But the real breakthrough is not the tokens, it’s the open-source biotech infrastructure replacing traditional pharma research systems. Here’s the real state of DeSci 2026. — ● The Open-Source AI Stack Powering DeSci The current DeSci momentum accelerated after peptAI reportedly designed an ADHD peptide candidate in 24 hours for only a few thousand dollars. Historically, drug discovery required years of research, massive pharma teams, and millions in upfront R&D. The infrastructure driving this shift includes: • OpenFold3 (by @open_fold) : open-source protein folding infrastructure. • RFdiffusion3 (by lead researcher @r_krishna3) : AI-driven protein and peptide generation. • Boltz-2 ( @Boltz_bio ): high-speed protein binding prediction. • ChEMBL ( @ChEMBL ) : open database with millions of bioactive compounds. • Federated protein training : collaborative biological AI training. • AI peptide agents : autonomous peptide discovery systems. • Bioactivity databases : open molecular research infrastructure. The real shift is biotech infrastructure moving from closed pharma systems onto open-source software rails. Projects like @Peptoma_xyz, @peptome_ai ( $PEPT ), @clarity_proto ( $FOLD ), and @BioLLM_ are building around AI-driven peptide discovery and on-chain biotech funding. — ● The Timeline Bottleneck AI Still Hasn’t Solved AI is accelerating discovery pipelines, but clinical validation remains the hardest challenge in biotech. Phase I: confirms the drug is safe for further testing. Phase II: determines whether the treatment actually works. Phase III: validates efficacy and safety before regulatory approval. AI is improving research speed and molecule discovery, but drug development still operates on multi-year timelines. No AI-designed drug has completed Phase III yet. — ● Updated 2026 DeSci Ecosystem Landscape Despite remaining a sub-$400M sector, DeSci led 24H narrative performance with a 1.64% gain while most major sectors stayed in red. The ecosystem is now expanding across specialized bioDAOs, AI-native discovery, scientific infrastructure, tokenized IP, and analytical tooling. • Capital Coordination Layer : funding decentralized scientific research. @vitadao @athenabiorg @anagenxyz @psy_dao @cryodao @spark_sciences @Spine_DAO @endrarediseases @QuantumBioDAO @Cerebrum_DAO @GenomesDAO @PoSciDonDAO @daohydra @eticaprotocol • AI Discovery Layer : AI-native drug discovery and biological modeling. @GeneStackDeBio @BioLLM_ @clarity_proto @Aubrai_ @Rejuve_AI @DeSci_Agents @cyberphysicsai • IP & Commercialization Layer : tokenizing biotech intellectual property. @Molecule_sci @AxonDAO • Data & Infrastructure Layer : decentralized scientific data and compute infrastructure. @origin_trail @GaleonCare @Hippo_Protocol @BluzelleHQ @GridcoinNetwork @dynexcoin @DataLakeToken @silencioNetwork • Publishing & Knowledge Layer : open-access publishing and peer review systems. @ResearchHub @nobleblocks • Consumer & Speculative Layer : retail biotech participation and experimental markets. @pumpdotscience @Open_Genome @D1ckGPT @peptidefolio • Analytical Tools : DeSci analytics, dashboards, and sector intelligence. @desciatoms @DeSciDashboard @TrackedBio @TBDeSci — ● Where DeSci Is Falling Behind DeSci still struggles with the mismatch between crypto’s short-term capital cycles and biotech’s long research timelines. Markets are pricing scientific potential far earlier than clinical validation, while funding volatility and governance inefficiencies continue slowing long-term research execution. That remains the biggest structural weakness in the DeSci narrative today. — ● Bull Case For DeSci The long-term opportunity is DeSci evolving into a new financing layer for biotech research. AI lowers research costs → bioDAOs fund experiments → IP gets tokenized → successful discoveries generate licensing revenue. That is why the global DeSci funding DAO market is projected to grow from $120M in 2025 to $520M by 2034, reflecting a 17.7% CAGR as scientific funding increasingly moves on-chain. — ● Bear Case For DeSci DeSci still faces major risks around regulation, DAO governance, tokenized IP legality, and integration with traditional academic institutions. Many early-stage DeSci projects still struggle with sustainable funding, researcher onboarding, and maintaining scientific rigor during speculative market cycles. The infrastructure trend is real, but scalable adoption and long-term value capture remain largely unproven. Still, DeSci remains one of the few crypto sectors attempting to build long-duration infrastructure beyond purely financial speculation.

Mars_DeFi's tweet photo. DeSci’s market cap has reached $384M as AI agents compress peptide drug discovery into 24-hour research pipelines.

But the real breakthrough is not the tokens, it’s the open-source biotech infrastructure replacing traditional pharma research systems.

Here’s the real state of DeSci 2026.

—
● The Open-Source AI Stack Powering DeSci
The current DeSci momentum accelerated after peptAI reportedly designed an ADHD peptide candidate in 24 hours for only a few thousand dollars.

Historically, drug discovery required years of research, massive pharma teams, and millions in upfront R&D.

The infrastructure driving this shift includes:
• OpenFold3 (by @open_fold) : open-source protein folding infrastructure.

• RFdiffusion3 (by lead researcher @r_krishna3) : AI-driven protein and peptide generation.

• Boltz-2 ( @Boltz_bio ): high-speed protein binding prediction.

• ChEMBL ( @ChEMBL ) : open database with millions of bioactive compounds.

• Federated protein training : collaborative biological AI training.

• AI peptide agents : autonomous peptide discovery systems.

• Bioactivity databases : open molecular research infrastructure.

The real shift is biotech infrastructure moving from closed pharma systems onto open-source software rails.

Projects like @Peptoma_xyz, @peptome_ai ( $PEPT ), @clarity_proto ( $FOLD ), and @BioLLM_ are building around AI-driven peptide discovery and on-chain biotech funding.

—
● The Timeline Bottleneck AI Still Hasn’t Solved
AI is accelerating discovery pipelines, but clinical validation remains the hardest challenge in biotech.

Phase I: confirms the drug is safe for further testing.

Phase II: determines whether the treatment actually works.

Phase III: validates efficacy and safety before regulatory approval.

AI is improving research speed and molecule discovery, but drug development still operates on multi-year timelines.

No AI-designed drug has completed Phase III yet.

—
● Updated 2026 DeSci Ecosystem Landscape

Despite remaining a sub-$400M sector, DeSci led 24H narrative performance with a 1.64% gain while most major sectors stayed in red.

The ecosystem is now expanding across specialized bioDAOs, AI-native discovery, scientific infrastructure, tokenized IP, and analytical tooling.

• Capital Coordination Layer : funding decentralized scientific research.
@vitadao
@athenabiorg
@anagenxyz
@psy_dao
@cryodao
@spark_sciences
@Spine_DAO
@endrarediseases
@QuantumBioDAO
@Cerebrum_DAO
@GenomesDAO
@PoSciDonDAO
@daohydra
@eticaprotocol

• AI Discovery Layer : AI-native drug discovery and biological modeling.
@GeneStackDeBio
@BioLLM_
@clarity_proto
@Aubrai_
@Rejuve_AI
@DeSci_Agents
@cyberphysicsai

• IP & Commercialization Layer : tokenizing biotech intellectual property.
@Molecule_sci
@AxonDAO

• Data & Infrastructure Layer : decentralized scientific data and compute infrastructure.
@origin_trail
@GaleonCare
@Hippo_Protocol
@BluzelleHQ
@GridcoinNetwork
@dynexcoin
@DataLakeToken
@silencioNetwork

• Publishing & Knowledge Layer : open-access publishing and peer review systems.
@ResearchHub
@nobleblocks

• Consumer & Speculative Layer : retail biotech participation and experimental markets.
@pumpdotscience
@Open_Genome
@D1ckGPT
@peptidefolio

• Analytical Tools : DeSci analytics, dashboards, and sector intelligence.
@desciatoms
@DeSciDashboard
@TrackedBio
@TBDeSci

—
● Where DeSci Is Falling Behind
DeSci still struggles with the mismatch between crypto’s short-term capital cycles and biotech’s long research timelines.

Markets are pricing scientific potential far earlier than clinical validation, while funding volatility and governance inefficiencies continue slowing long-term research execution.

That remains the biggest structural weakness in the DeSci narrative today.

—
● Bull Case For DeSci
The long-term opportunity is DeSci evolving into a new financing layer for biotech research.

AI lowers research costs → bioDAOs fund experiments → IP gets tokenized → successful discoveries generate licensing revenue.

That is why the global DeSci funding DAO market is projected to grow from $120M in 2025 to $520M by 2034, reflecting a 17.7% CAGR as scientific funding increasingly moves on-chain.

—
● Bear Case For DeSci
DeSci still faces major risks around regulation, DAO governance, tokenized IP legality, and integration with traditional academic institutions.

Many early-stage DeSci projects still struggle with sustainable funding, researcher onboarding, and maintaining scientific rigor during speculative market cycles.

The infrastructure trend is real, but scalable adoption and long-term value capture remain largely unproven.

Still, DeSci remains one of the few crypto sectors attempting to build long-duration infrastructure beyond purely financial speculation.

124

14K

dmschoi retweeted

Hans

@dmschoi

Who to follow

Last Seen Users on Sotwe

Trends for you

Most Popular Users